A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
← catalyst calendarNCT07161414 · readout in 333 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
40estimated
Sites
11
Countries
South Korea, Spain, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-25 | actual | When the study began enrolling |
| Primary completion | 2027-07-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-24 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: IV Rilvegostomig — also filed as AZD2936
- Drug: Recombinant Human Hyaluronidase (rHu)
- Drug: SC Rilvegostomig — also filed as AZD2936
- Drug: SC rilvegostomig + rHu
Primary outcome
what the primary-completion date above is the date OFArea under the Concentration-time Curve During One Dosing Interval (AUCtau)
measured From Day 1 up to end of Cycle 2 in Part 1 and end of Cycle 1 in Part 2 (each cycle will be of 3 weeks)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed